INmune Bio (INMB) to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th

Go back to INmune Bio (INMB) to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
(NASDAQ: INMB) Delayed: 1.49 +0.06 (4.20%)
Previous Close $1.43    52 Week High
Open $1.39    52 Week Low
Day High $1.49    P/E N/A 
Day Low $1.39    EPS
Volume 61,561